We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics and advanced technologies.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Behind the science
Discover how we're getting ahead
Antibiotic resistance: now’s the time to prevent the next pandemic
Getting ahead of COPD exacerbations using new tech could save lives
The logic of biologic medicines: advancing care for people with immune-mediated conditions
Eosinophils could be holding the missing link between symptoms, diagnosis and treatment
Time for a change: personalising asthma treatment
Unlocking the power of the immune system to get ahead of hepatitis B
Tackling tomorrow’s health challenges today
How vaccine science can help tackle antimicrobial resistance
The 40 year fight against HIV
How the next generation of immuno-oncology could help us get ahead of cancer
Life at GSK
How we help people thrive
Diversity, equity and inclusion
Positively impacting society and the planet
Pricing and access
We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.
Global health and health security
We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.
Diversity, equity and inclusion
Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.
We are working towards a net zero impact on climate and a net positive impact on nature by 2030, across our full value chain.
Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.
In the spotlight
GSK on social
Emerging evidence suggests that climate change could be worsening #AntiMicrobialResistance. Another sign of how climate and health are closely connected. We're working hard to reduce our climate impact and to find new tools to help get ahead of #AMR, together. twitter.com/wellcometrust/…Twitter @GSK Nov 30
Organ damage impacts many people living with #lupus within 5 years of diagnosis. A new global survey of healthcare professionals suggests conversations with patients about #SLE organ damage risk may not be happening early enough in course of disease. gsk.to/3EMv4wzTwitter @GSK Nov 29
Excellent news from @DHSCgovuk today with investment to support UK status as a #ScienceSuperpower. The UK life sciences sector delivers transformational medicines and vaccines to patients around the world, while also being a key generator of jobs and growth. twitter.com/DHSCgovuk/stat…Twitter @GSK Nov 28
An estimated 37m people in the Greater Horn of Africa region are facing acute food insecurity due to conflict and extreme weather. We're contributing £1m to @savechildrenuk and @Amref_UK to treat children with malnutrition and provide access to health services.Twitter @GSK Nov 24
#WorldAntimicrobialAwarenessWeek is once a year, but we’re working hard every day to get ahead of #AMR together – from supporting surveillance and stewardship to R&D into potential therapies and vaccines. Go #BehindtheScience to learn more 👇gsk.com/en-gb/behind-t…ZTwitter @GSK Nov 24
#AntimicrobialResistance means that antibiotics are becoming less effective. That can impact even common conditions like urinary tract infections. So we’re working hard to find new tools to help us get ahead of #AMR, together. #WAAW gsk.com/en-gb/behind-t…Twitter @GSK Nov 23
It’s #WAAW, take #AMomentToReset and find out how we can get ahead of AMR, together. Antibiotics are a cornerstone of modern healthcare but #AntimicrobialResistance means they’re becoming less effective. Left unchecked, #AMR could claim 10M lives by 2050.Twitter @GSK Nov 23
This #WorldCOPDDay we are discussing the importance of treatable traits in #COPD and how they can guide tailored treatment decisions to improve symptoms, reduce the burden of exacerbations and improve the lives of those impacted by the disease.
The 2023 GOLD recommendations continue to simplify the approach to COPD diagnosis and management, with a focus on improving patient’s symptoms and reducing risk of exacerbations. This is consistent with GSK’s scientific position and reflect what is best for patients. twitter.com/GOLD_COPD/stat…
Sharai, Automation Engineering Associate, is on rotation in the GSK graduate scheme where she receives the first-class support she needs to thrive as she grows her career. Hear her story 👇 #AheadTogetherrZ